Profound Medical Corp.
Profound Medical Corp. (PRN.TO) Financial Performance & Income Statement Overview
Review Profound Medical Corp. (PRN.TO) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Profound Medical Corp. (PRN.TO) Income Statement & Financial Overview
View the income breakdown for Profound Medical Corp. PRN.TO across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $3.71M | $2.83M | $2.23M | $1.91M |
| Cost of Revenue | $1.18M | $1.03M | $795000.00 | $641000.00 |
| Gross Profit | $2.52M | $1.81M | $1.44M | $1.27M |
| Gross Profit Ratio | $0.68 | $0.64 | $0.64 | $0.66 |
| R&D Expenses | $4.68M | $4.15M | $4.19M | $3.93M |
| SG&A Expenses | $6.60M | $6.64M | $5.08M | $4.82M |
| Operating Expenses | $11.28M | $10.79M | -$6.39M | $8.75M |
| Total Costs & Expenses | $12.46M | $11.82M | $10.07M | $9.39M |
| Interest Income | $0.00 | $0.00 | $786754.00 | $850963.00 |
| Interest Expense | $0.00 | $199000.00 | -$147246.00 | -$471037.00 |
| Depreciation & Amortization | $76000.00 | $268000.00 | $287000.00 | $411321.00 |
| EBITDA | -$8.68M | -$8.72M | -$7.55M | -$7.66M |
| EBITDA Ratio | -$2.34 | -$3.08 | -$3.38 | -$4.009 |
| Operating Income | -$8.76M | -$8.99M | $7.83M | -$7.48M |
| Operating Income Ratio | -$2.36 | -$3.17 | $3.51 | -$3.92 |
| Other Income/Expenses (Net) | $3.19M | -$199000.00 | -$14.73M | $1.32M |
| Income Before Tax | -$5.57M | -$9.19M | -$6.90M | -$6.16M |
| Income Before Tax Ratio | -$1.50 | -$3.24 | -$3.09 | -$3.23 |
| Income Tax Expense | -$238000.00 | $177000.00 | $20000.00 | $39000.00 |
| Net Income | -$5.33M | -$9.36M | -$6.92M | -$6.20M |
| Net Income Ratio | -$1.44 | -$3.31 | -$3.10 | -$3.25 |
| EPS | -$0.27 | $0.00 | -$0.28 | -$0.26 |
| Diluted EPS | -$0.27 | $0.00 | -$0.28 | -$0.26 |
| Weighted Avg Shares Outstanding | $25.77M | $0.00 | $24.44M | $23.84M |
| Weighted Avg Shares Outstanding (Diluted) | $25.77M | $0.00 | $24.44M | $23.84M |
Financial performance has remained strong, with revenue growing from $1.91M in Q1 2024 to $3.71M in Q4 2024. Gross profit continued to perform well, with margins at 68% in the latest quarter. Operating income reached -$8.76M in Q4 2024, holding a steady -236% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$8.68M. Net income rose to -$5.33M, keeping EPS at -$0.27. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan